Temenos Launches SaaS Explainable AI Models to Help Banks Support Small Businesses and Retail Customers During COVID-19 Crisis
Temenos (SIX: TEMN), the banking software company, announced today the launch of Explainable AI (XAI) models to enable banks and credit unions to rapidly offer loans to small and medium enterprises (SMEs) that have seen their cash flow disrupted by the COVID-19 outbreak. These patented XAI models allow banks to accelerate digital onboarding, conduct eligibility checks and process loan applications for SMEs and retail customers. The models are available as part of the Temenos AI portfolio or can be integrated with Temenos Infinity, the leading digital omnichannel product, and are delivered as Temenos SaaS for fast and scalable deployment.
Max Chuard, Chief Executive Officer, Temenos, said: “These are challenging times for small businesses in particular. As the leader in banking software, Temenos is committed to innovation that not only keeps banks and the global economy running, but also helps SMEs and retail customers access funding at a time of financial distress. We are delivering our cloud-native, advanced AI banking software as SaaS to enable banks qualify and process loans rapidly. I am proud that with our technology we can provide banks with a modern digital banking platform and decision-making capabilities, allowing them to move incredibly fast and compress projects that would usually take months into days.”
Temenos’ XAI models help banks make urgent lending decisions that are transparent and explainable in human language to the end-users, customers and the regulators. These models enable banks to identify appropriate products that carry an acceptable level of risk for both the customer and the bank. The SME model, in particular, provides on average over 25% greater accuracy compared to the risk score provided by leading credit bureaus, allowing banks to increase their pass rate by 20% while keeping defaults under control.
The new XAI models enable banks to take into account a wide range of variables when making lending decisions, such as additional incomes, new cost reductions, and alternative forms of collateral. Temenos XAI models can instantly calculate the impact of new variables and suggest additional terms and conditions.
As a result of the pandemic, banks are being asked to lend in unusual circumstances, requiring them to manage the twin pressures of increasing arrears and political pressure not to trigger defaults. Government Initiatives like the UK Coronavirus Business Interruption Loan Scheme (CBILS) and the US Paycheck Protection Program (PPP) are aiming to help SMEs in need of financial support by promoting emergency bank loans.
Jerry Silva, Research Vice President, IDC, said: “A record number of small businesses and individuals are now applying for loans and financial relief. In the face of this demand, banks need to respond by providing digital self-service user journeys, quickly conducting eligibility checks, adhering to bank risk criteria, and establishing appropriate pricing. Solutions like Temenos’ new XAI models are designed to help banks accelerate the loan application process by centralizing and enforcing policy rules using AI to ensure decisions are based on bank-specified criteria while maintaining transparency with customers and maintaining compliance and risk controls.”
These API-driven XAI models can be rolled out with the associated policy rules, allowing smart decision-making with minimal integration that can be deployed in the cloud in days or just a few weeks. This consistency in decision-making helps frontline staff by reducing the need for manual intervention, which can slow the processing of the huge volumes of applications being considered. Temenos’ XAI models can be used by any business user with minimum reliance on the IT department.
The XAI models available worldwide include:
- Temenos AI – SME Smart Decisioning: Temenos provides centrally created support for decision makers at the front line, for on-boarding, edibility checks and rapid loan processing. Furthermore, it reduces the need for human intervention in underwriting departments. The model is already proven with blue-chip UK lenders and can rapidly augment the decision-making processes already in place.
- Temenos AI – Urgent Relief Loan: Identify customers with a significant drop in income, who are at financial risk and offer further credit or credit deferral products.
- Temenos AI – Personalization: Offer personalized products to customers in real-time based on their changing behaviors and needs identified using Explainable AI models
- Temenos AI – Loan Pre-Approvals: Lending pre-approval for all customers. Expedite short- term urgent lending to the greatest number of customers.
- Temenos AI – Digital Financial Advice: Identify customers who are unlikely to be able to continue without finding a new source of income, hence both reducing risk and offering the opportunity to provide suitable financial solutions to them.
– Ends –
About Temenos
Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 500 million banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200422005802/en/
Contact information
Jessica Wolfe & Grace Collins
Temenos Global Public Relations
Tel: +1 610 232 2793 & + 44 20 7423 3969
Email : press@temenos.com
Alistair Kellie & Andrew Adie
Newgate Communications on behalf of Temenos
Tel: +44 20 7680 6550
Email: allnewgatetemenos@newgatecomms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MarkLines Gen-AI Beta Version Released for Automotive Industry13.1.2026 02:00:00 EET | Press release
MarkLines Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Makoto Sakai; TYO:3901) announced its launch of the "MarkLines Gen-AI Beta Version," the new feature for B2B users in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112383839/en/ "MarkLines Gen-AI Beta Version" can take questions in natural language and instantly give highly reliable, relevant data drawn from MarkLines’ extensive automotive database (Image: MarkLines Co., Ltd.) This AI-powered feature enables users to ask questions in natural language and instantly receive highly reliable, relevant data drawn from MarkLines’ extensive automotive database. Moreover, the system analyzes this information by leveraging the rich content across its platform and delivers clear, concise, text-based insights. By combining trusted data with advanced analytical capabilities through generative AI, this service represents a first-of-its-kind
Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 23:30:00 EET | Press release
Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the cornerstone of Australia’s secure military communications since IS-22’s launch in 2012. SES will build a dedicated ground segmen
NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 23:05:00 EET | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 21:00:00 EET | Press release
Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain and stiffness in the global Phase 3 MANEUVER study
Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 20:32:00 EET | Press release
Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112241557/en/ Ricimed - Fabentech Ricimed®, an antidote against one of the most toxic natural substances in the world In addition to supportive care, and in severe situations requiring immediate administration, Ricimed® represents a new therapeutic option for the management of acute ricin intoxication. Ricin, among the most dangerous naturally occurring substances, can cause death within hours or days regardless of the route of exposure, making it a major biological threat for many countries. Having demonstrated its ability to specifically target and neutralize ricin before irreversible damage occurs, Ricimed® is an antibody-based therapy relying on poly
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
